

Recommendations from York and Scarborough Medicines Commissioning Committee September 2016

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Dulaglutide	Diabetes	Approved for formulary inclusion	<p>In comparison to exenatide ER, the licensed indications for dulaglutide are broader to include use as monotherapy and in combination with insulin.</p> <p>Dulaglutide (unlike exenatide ER) is licensed for use without dose adjustment in patients with moderate renal impairment.</p> <p>Dulaglutide is available via an automated pen device which may benefit patients and carers/nursing</p>	Recommended for formulary inclusion as the first choice weekly preparation. Exenatide weekly preparation will remain on formulary as an alternative option	Green	Cost neutral as marginally cheaper than exenatide weekly

			teams.			
Co-danthramer/co-danthrusate	All	Issue reminder to prescribers that these products are to be discontinued	Formulary currently highlights impending discontinuation of these products, however Y&S primary care prescribing Q1-Q4 2015 stands at 192 items (£12,729).	-	Restricted product	-
Revised TEWV Transfer of Prescribing Guideline		The MCC supports the proposed changes to the Safe Transfer of Prescribing Guidance with regard to its implications for VoY CCG	The TEWV transfer of prescribing guidance was due for review in January 2016. The guideline has been updated to reflect recent formulary decisions including; new drugs, shared care arrangements and national guidance.	-	Various	Most of the drug status changes have already been considered through D&T / MCC and as such the financial impact of these decisions have already been considered. The implementation of NICE guidance in relation to antipsychotic prescribing will have a

						significant impact upon TEWV.
Buprenorphine 7 day patch	Treatment of non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia	Butec [®] was the agreed choice of branded generic for use across Y&S	MCC considered a briefing paper which concluded that Butec [®] was similar to Butrans [®] but was a cheaper option.	-	Green (CD)	Represents a cost saving against Butrans [®]
Formulary amendments	Formulary updated in line with NICE TA401, TA402, TA405	-	-	-	-	NHSE commissioned